34 related articles for article (PubMed ID: 38319859)
1. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial.
Schadendorf D; Luke JJ; Ascierto PA; Long GV; Rutkowski P; Khattak A; Del Vecchio M; de la Cruz-Merino L; Mackiewicz J; Sileni VC; Kirkwood JM; Robert C; Grob JJ; Dummer R; Carlino MS; Zhao Y; Kalabis M; Krepler C; Eggermont A; Scolyer RA
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485189
[TBL] [Abstract][Full Text] [Related]
2. Melanoma neoantigen vaccines: Are we getting more personal now?
Latifyan S; Haanen JB
Med; 2024 Apr; 5(4):288-290. PubMed ID: 38614074
[TBL] [Abstract][Full Text] [Related]
3. Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study.
Christensen SK; Winther ML; Laursen IJ; Madsen FS; Brink C; Brix TH; Ellebaek E; Svane IM; Hansen FS; Haslund C; Laursen OK; Schmidt H; Larsen ID; Bastholt L; Ruhlmann CH
Support Care Cancer; 2024 Apr; 32(5):281. PubMed ID: 38598052
[TBL] [Abstract][Full Text] [Related]
4. Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont
Weber J; Mandala M; Ascierto PA; Larkin J
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35042825
[No Abstract] [Full Text] [Related]
5. Adjuvant Immunotherapy in Stage II Melanoma-Further Risk Stratification is Needed.
Rashdan H; Adamson AS; Semenov YR
JAMA Dermatol; 2024 Apr; 160(4):385-386. PubMed ID: 38477923
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab for the adjuvant treatment of IIB or IIC melanoma.
Rutkowski P; Czarnecka AM
Expert Rev Anticancer Ther; 2023; 23(9):897-902. PubMed ID: 37573515
[TBL] [Abstract][Full Text] [Related]
7. Treatment of High Risk Resected Melanoma in Australia: Current Landscape and Practises.
Bhave P; Haydon A
Australas J Dermatol; 2020 Aug; 61(3):203-209. PubMed ID: 32403192
[TBL] [Abstract][Full Text] [Related]
8. Progression/Recurrence-Free Survival 2 in Adjuvant Melanoma.
Augustin RC; Luke JJ
NEJM Evid; 2022 Nov; 1(11):EVIDe2200240. PubMed ID: 38319859
[TBL] [Abstract][Full Text] [Related]
9. Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma.
Eggermont AMM; Kicinski M; Blank CU; Mandala M; Long GV; Atkinson V; Dalle S; Haydon A; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Boers-Sonderen M; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; van Akkooi ACJ; Lorigan P; Grebennik D; Krepler C; Marreaud S; Suciu S; Robert C
NEJM Evid; 2022 Nov; 1(11):EVIDoa2200214. PubMed ID: 38319852
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Kennedy OJ; Glassee N; Kicinski M; Blank CU; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Boers-Sonderen M; Giacomo AMD; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; van Akkooi ACJ; Gandini S; Buhrer E; Suciu S; Robert C; Eggermont AMM; Mandala M; Lorigan P; Valpione S
Eur J Cancer; 2024 Apr; 201():113585. PubMed ID: 38402687
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
Eggermont AMM; Blank CU; Mandalà M; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; van Akkooi ACJ; Krepler C; Ibrahim N; Marreaud S; Kicinski M; Suciu S; Robert C;
Lancet Oncol; 2021 May; 22(5):643-654. PubMed ID: 33857412
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study.
Li T; Jia DD; Teng LS
Invest New Drugs; 2020 Oct; 38(5):1334-1341. PubMed ID: 32072356
[TBL] [Abstract][Full Text] [Related]
13. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.
Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; van Akkooi ACJ; Krepler C; Ibrahim N; Marreaud S; Kicinski M; Suciu S; Robert C
J Clin Oncol; 2020 Nov; 38(33):3925-3936. PubMed ID: 32946353
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
